Staff

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design...

Harnessing the Power of Laboratory Data to Optimize Trial Design, Site Identification and Patient Recruitment, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how data-driven services can address the challenges that contributing factors raise in clinical trial design,...

error: Content is protected !!